The Obesity drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. According to WHO, overweight is defined as a BMI greater than or equal to 25 and obesity as a BMI greater than or equal to 30. Kenya has seen increase in abdominal obesity, poor dietary habits, excess alcohol consumption and physical inactivity over the past few decades. Anti-obesity drugs are pharmacological agents that are used to lose cholesterol and reduce the body weight. Likelihood of obesity is higher among women, urban residents, and individuals with high education and wealth in Kenya.
The market is majorly driven by the rising burden of Obesity in Kenya. According to CDC (Centre of Diseases Control), the prevalence of overweight was 20.5%, and the prevalence of obesity, 9.1% among women in Kenya. This increasing prevalence is associated with urbanization, access to and consumption of high-calorie diets, and decreased physical activity.
In a study published by Pan African Medical Journal, the overall prevalence of overweight was 18.9 % and obesity was 9.1% among general population in Kenya. Sociodemographic factors associated with overweight, or obesity include middle aged, female sex, higher socio-economic status, urban residence, and ethnicity. Obesity is directly linked with several chronic NCDs such as hypertension and type 2 diabetes.
However, Lack of proper education against weight management, low efficacy of drugs and side-effects of the obesity medications are restraining market growth.